A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Not Recruiting

Trial ID: NCT00226980


The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.

Official Title

A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent

   - Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program.

   - Male or female 18 years or older

   - Willing to use contraception

   - Pathologic diagnosis of renal cell carcinoma

   - Bi-dimensionally measurable disease

   - Evidence of disease progression prior to start of treatment

   - Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy

   - Adequate hematologic data: ANC.1.5; platelets>100x10^9

   - Adequate renal function: Creatinine clearance .50cc

   - Adequate liver function: Alkaline phos <3XULN AST/ALT <3XULN T.Bili <1.5XULN

   - ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases.

   - Peripheral neuropathy.

   - Pregnant and/ or lactating female.

   - Unable to take a baby aspirin.


drug: Thalidomide

drug: Capecitabine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas

New Trial Alerts